Simon P. Newman
Endocrinology and Metabolic Medicine
Faculty of Medicine
Imperial College London
St Mary's Hospital
UK
Name/email consistency: high
- STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Newman, S.P., Foster, P.A., Stengel, C., Day, J.M., Ho, Y.T., Judde, J.G., Lassalle, M., Prevost, G., Leese, M.P., Potter, B.V., Reed, M.J., Purohit, A. Clin. Cancer Res. (2008)
- The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Newman, S.P., Foster, P.A., Ho, Y.T., Day, J.M., Raobaikady, B., Kasprzyk, P.G., Leese, M.P., Potter, B.V., Reed, M.J., Purohit, A. Br. J. Cancer (2007)
- Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Newman, S. Curr. Opin. Investig. Drugs (2007)
- The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Newman, S.P., Ireson, C.R., Tutill, H.J., Day, J.M., Parsons, M.F., Leese, M.P., Potter, B.V., Reed, M.J., Purohit, A. Cancer Res. (2006)